(Q37982214)

26 August 2017

title

Clinical management of elderly patients with type 2 diabetes mellitus (English)

1 reference

26 August 2017

0 references

Richard E Pratley

1

1 reference

26 August 2017

Matthew Gilbert

series ordinal

2

1 reference

26 August 2017

language of work or name

English

0 references

publication date

1 January 2012

1 reference

26 August 2017

published in

Postgraduate Medicine

1 reference

26 August 2017

volume

124

1 reference

26 August 2017

issue

1

1 reference

26 August 2017

page(s)

133-143

1 reference

Standards of medical care in diabetes--2011.

26 August 2017

cites work

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2012.01.2526

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2012.01.2526

A call to incorporate the prevention and treatment of geriatric disorders in the management of diabetes in the elderly

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2012.01.2526

Impact of recent increase in incidence on future diabetes burden: U.S., 2005-2050.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2012.01.2526

Type 2 diabetes and risk for functional decline and disability in older persons.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2012.01.2526

Trends in the prevalence and comorbidities of diabetes mellitus in nursing home residents in the United States: 1995-2004.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2012.01.2526

Mortality in adults with and without diabetes in a national cohort of the U.S. population, 1971-1993

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2012.01.2526

Associations of diabetes mellitus with total life expectancy and life expectancy with and without cardiovascular disease

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2012.01.2526

Economic costs of diabetes in the U.S. In 2007.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2012.01.2526

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2012.01.2526

Independent influence of age on basal insulin secretion in nondiabetic humans. European Group for the Study of Insulin Resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2012.01.2526

Unique characteristics of the geriatric diabetic population and the role for therapeutic strategies that enhance glucagon-like peptide-1 activity

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2012.01.2526

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2012.01.2526

Aging and insulin secretion

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2012.01.2526

Endocytosis of low-density lipoprotein by human pancreatic beta cells and uptake in lipid-storing vesicles, which increase with age.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2012.01.2526

Islet amyloid in type 2 diabetes, and the toxic oligomer hypothesis

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2012.01.2526

Beta-cell deficit and increased beta-cell apoptosis in humans with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2012.01.2526

New approaches to treating type 2 diabetes mellitus in the elderly: role of incretin therapies.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2012.01.2526

Pharmacologic management of the older patient with type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2012.01.2526

Association between adiposity in midlife and older age and risk of diabetes in older adults

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2012.01.2526

Low free testosterone predicts frailty in older men: the health in men study

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2012.01.2526

Prevalence, expenditures, and complications of multiple chronic conditions in the elderly

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2012.01.2526

Treatment of patients over 64 years of age with type 2 diabetes: experience from nateglinide pooled database retrospective analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2012.01.2526

Association of diabetes, comorbidities, and A1C with functional disability in older adults: results from the National Health and Nutrition Examination Survey (NHANES), 1999-2006

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2012.01.2526

10-year follow-up of intensive glucose control in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2012.01.2526

Glycemic control, complications, and death in older diabetic patients: the diabetes and aging study

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2012.01.2526

Falling into the coverage gap: Part D drug costs and adherence for Medicare Advantage prescription drug plan beneficiaries with diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2012.01.2526

Treatment of type 2 diabetes and outcomes in patients with heart failure: a nested case-control study from the U.K. General Practice Research Database

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2012.01.2526

Insulin therapy in the elderly patient with diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2012.01.2526

Thiazolidinediones and cardiovascular outcomes in older patients with diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2012.01.2526

Comparison of cardiovascular outcomes in elderly patients with diabetes who initiated rosiglitazone vs pioglitazone therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2012.01.2526

Rosiglitazone-associated fractures in type 2 diabetes: an Analysis from A Diabetes Outcome Progression Trial (ADOPT).

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2012.01.2526

Use of thiazolidinediones and fracture risk

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2012.01.2526

Long-term use of thiazolidinediones and fractures in type 2 diabetes: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2012.01.2526

Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with Type 2 diabetes (LEAD-1 SU)

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2012.01.2526

Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)-2 study

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2012.01.2526

Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 met+SU): a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2012.01.2526

Efficacy and safety of the human glucagon-like peptide-1 analog liraglutide in combination with metformin and thiazolidinedione in patients with type 2 diabetes (LEAD-4 Met+TZD).

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2012.01.2526

Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2012.01.2526

Dipeptydil peptidase-4 inhibitors in type 2 diabetes: a meta-analysis of randomized clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2012.01.2526

Alogliptin use in elderly people: a pooled analysis from phase 2 and 3 studies

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2012.01.2526

Management of type 2 diabetes in treatment-naive elderly patients: benefits and risks of vildagliptin monotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2012.01.2526

Efficacy and safety of saxagliptin in older patients with type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2012.01.2526

Comparison of vildagliptin and metformin monotherapy in elderly patients with type 2 diabetes: a 24-week, double-blind, randomized trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2012.01.2526

Efficacy and tolerability of sitagliptin monotherapy in elderly patients with type 2 diabetes: a randomized, double-blind, placebo-controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2012.01.2526

Colesevelam lowers glucose and lipid levels in type 2 diabetes: the clinical evidence

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2012.01.2526

Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2012.01.2526

21 January 2018

Identifiers

DOI

10.3810/PGM.2012.01.2526

1 reference

26 August 2017

1 reference